콘텐츠로 건너뛰기
Merck
  • Comparative analyses of plasma amyloid-β levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system.

Comparative analyses of plasma amyloid-β levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system.

Science advances (2019-04-20)
YoungSoo Kim, Yong Kyoung Yoo, Hye Yun Kim, Jee Hoon Roh, Jinsik Kim, Seungyeop Baek, Jinny Claire Lee, Hye Jin Kim, Myung-Sic Chae, Dahye Jeong, Dongsung Park, Sejin Lee, HoChung Jang, Kyeonghwan Kim, Jeong Hoon Lee, Byung Hyun Byun, Su Yeon Park, Jeong Ho Ha, Kyo Chul Lee, Won Woo Cho, Jae-Seung Kim, Jae-Young Koh, Sang Moo Lim, Kyo Seon Hwang
초록

Detection of amyloid-β (Aβ) aggregates contributes to the diagnosis of Alzheimer disease (AD). Plasma Aβ is deemed a less invasive and more accessible hallmark of AD, as Aβ can penetrate blood-brain barriers. However, correlations between biofluidic Aβ concentrations and AD progression has been tenuous. Here, we introduce a diagnostic technique that compares the heterogeneous and the monomerized states of Aβ in plasma. We used a small molecule, EPPS [4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid], to dissociate aggregated Aβ into monomers to enhance quantification accuracy. Subsequently, Aβ levels of EPPS-treated plasma were compared to those of untreated samples to minimize inter- and intraindividual variations. The interdigitated microelectrode sensor system was used to measure plasma Aβ levels on a scale of 0.1 pg/ml. The implementation of this self-standard blood test resulted in substantial distinctions between patients with AD and individuals with normal cognition (NC), with selectivity and sensitivity over 90%.